Literature DB >> 12065493

Role of signal sequence in vaccine-induced protection against experimental coccidioidomycosis.

Chengyong Jiang1, D Mitchell Magee, F Douglas Ivey, Rebecca A Cox.   

Abstract

The vaccine efficacy of the gene sequence encoding the signal peptide of the antigen known as antigen 2 or proline-rich antigen (Ag2/PRA), an immunodominant antigen present in the cell wall of the fungal pathogen Coccidioides immitis, was investigated in a murine model of coccidioidomycosis. Expression plasmids for Ag2/PRA(1-18) DNA (signal sequence), Ag2/PRA(19-194) DNA (lacking the signal sequence), and Ag2/PRA(1-194) DNA (full length) were inserted in the pVR1012 vector, and the constructs were used to vaccinate the highly susceptible BALB/c mouse strain. Immunization with the signal gene sequence significantly reduced the fungal burden in the lungs and spleens of mice 12 days after intraperitoneal challenge with a lethal dose of 2,500 C. immitis arthroconidia, to a level comparable to the protection induced in mice immunized with the full-length Ag2/PRA(1-194) DNA. The Ag2/PRA(19-194) gene protected mice but to a significantly lower level than the signal sequence or the full-length Ag2 gene. The immunizing capacity of Ag2/PRA(1-18) was not attributable to a nonspecific immunostimulatory effect of DNA, as evidenced by the fact that mice immunized with a frameshift mutation of Ag2/PRA(1-18) were not protected against challenge. Furthermore, a synthetic peptide corresponding to the translated sequence of Ag2/PRA(1-18) DNA protected mice, albeit at a lower level than the Ag2/PRA(1-18) DNA vaccine. The protection induced with the signal gene vaccine correlated with the production of gamma interferon when splenocytes from Ag2/PRA(1-18)-immunized mice were stimulated with recombinant full-length Ag2 and was not associated with the production of anti-Coccidioides immunoglobulin G antibody. This is the first study to establish that a signal peptide sequence alone, administered as a gene vaccine or synthetic peptide, can induce protective immunity against a microbial pathogen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065493      PMCID: PMC128064          DOI: 10.1128/IAI.70.7.3539-3545.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen.

Authors:  D R Drew; M Lightowlers; R A Strugnell
Journal:  Vaccine       Date:  2000-05-22       Impact factor: 3.641

2.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  IMMUNIZATION OF MICE TO COCCIDIOIDES IMMITIS: DOSE, REGIMEN AND SPHERULATION STAGE OF KILLED SPHERULE VACCINES.

Authors:  H B LEVINE; Y C KONG; C SMITH
Journal:  J Immunol       Date:  1965-01       Impact factor: 5.422

4.  Immunogenicity of spherule-endospore vaccines of Coccidioides immitis for mice.

Authors:  H B LEVINE; J M COBB; C E SMITH
Journal:  J Immunol       Date:  1961-08       Impact factor: 5.422

5.  Spectrum of in vivo and in vitro cell-mediated immune responses in coccidioidomycosis.

Authors:  R A Cox; J R Vivas
Journal:  Cell Immunol       Date:  1977-06-01       Impact factor: 4.868

6.  Immunostimulatory DNA sequences influence the course of adjuvant arthritis.

Authors:  Arash Ronaghy; Berent J Prakken; Kenji Takabayashi; Gary S Firestein; David Boyle; Nathan J Zvailfler; Sarah T A Roord; Salvatore Albani; Dennis A Carson; Eyal Raz
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

7.  In vitro lymphocyte responses of coccidioidin skin test-positive and -negative persons to coccidioidin, spherulin, and a coccidioides cell wall antigen.

Authors:  R A Cox; E Brummer; G Lecara
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

8.  DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Authors:  Giovanni Delogu; Amy Li; Charlene Repique; Frank Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

9.  Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis.

Authors:  P Q Patek; J L Collins; M Cohn
Journal:  Nature       Date:  1978-11-30       Impact factor: 49.962

10.  Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.

Authors:  S L Baldwin; C D D'Souza; I M Orme; M A Liu; K Huygen; O Denis; A Tang; L Zhu; D Montgomery; J B Ulmer
Journal:  Tuber Lung Dis       Date:  1999
View more
  13 in total

1.  A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.

Authors:  Eric J Tarcha; Venkatesha Basrur; Chiung-Yu Hung; Malcolm J Gardner; Garry T Cole
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.

Authors:  Magdalena K Bielecka; Nathalie Devos; Mélanie Gilbert; Miao-Chiu Hung; Vincent Weynants; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

3.  Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development.

Authors:  Riva Kovjazin; Ilan Volovitz; Yair Daon; Tal Vider-Shalit; Roy Azran; Lea Tsaban; Lior Carmon; Yoram Louzoun
Journal:  Mol Immunol       Date:  2011-02-12       Impact factor: 4.407

Review 4.  Advances in combating fungal diseases: vaccines on the threshold.

Authors:  Jim E Cutler; George S Deepe; Bruce S Klein
Journal:  Nat Rev Microbiol       Date:  2006-12-11       Impact factor: 60.633

Review 5.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.

Authors:  Roger A Herr; Chiung-Yu Hung; Garry T Cole
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

7.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

8.  Characterization of novel multiantigenic vaccine candidates with pan-HLA coverage against Mycobacterium tuberculosis.

Authors:  Riva Kovjazin; David Shitrit; Rachel Preiss; Ilanit Haim; Lev Triezer; Leonardo Fuks; Abdel Rahman Nader; Meir Raz; Ritta Bardenstein; Galit Horn; Nechama I Smorodinsky; Lior Carmon
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

9.  Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate.

Authors:  Kris I Orsborn; Lisa F Shubitz; Tao Peng; Ellen M Kellner; Marc J Orbach; Paul A Haynes; John N Galgiani
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Ensuring safety of DNA vaccines.

Authors:  Jacob Glenting; Stephen Wessels
Journal:  Microb Cell Fact       Date:  2005-09-06       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.